Nanobiotix Reports Q1 2026 Progress, Highlights 85.7% Response Rate In Phase 2 JNJ-1900 NSCLC Study, FDA Acceptance Of NANORAY-312 Protocol Amendment; Company Believes That The Net Proceeds From The Recent Follow-On Offering, Together With Its Cash And Cash Equivalents Of €42.1 Million As Of March 31, 2026

Loading news article.

Nanobiotix Reports Q1 2026 Progress, Highlights 85.7% Response Rate In Phase 2 JNJ-1900 NSCLC Study, FDA Acceptance Of NANORAY-312 Protocol Amendment; Company Believes That The Net Proceeds From The Recent Follow-On Offering, Together With Its Cash And Cash Equivalents Of €42.1 Million As Of March 31, 2026 | WAPE

Article summary

Related companies

Comments —